Theralink Technologies

THER

Biotechnology · Healthcare

Price

$0.00

+0.00 (+0.00%)

Market Cap

$615,149

Winston Score

Winston is serious

Below-average fundamentals — multiple weak pillars.

Share count rising — dilution

+1243021.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 495K (2019) → 6.15B (2023)

Theralink Technologies is a small biotechnology company focused on helping doctors choose the right cancer treatments for individual patients. It uses a lab-based testing process called proteomics, which analyzes proteins in tumor samples to predict how a patient's cancer might respond to specific drugs. The company primarily serves oncologists, cancer centers, and pharmaceutical companies conducting clinical trials.

Theralink earns revenue by charging for its diagnostic testing services and through partnerships with drug developers who use its platform to study how patients respond to therapies. It operates mainly in the United States and is a very small company, with a market cap near zero, meaning it carries significant financial risk. The deeply negative operating margin shows the company spends far more than it earns, and its main challenge is scaling revenue fast enough to survive — access to additional funding will likely determine whether the business can continue operating.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-41.3% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+223.1% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

0.0%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~2 months

$997,484 cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Cash watch

Theralink Technologies has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

77.7%

Premium pricing power — 77.7% gross margin

Operating Margin

-1302.9%

Losing money on operations — -1302.9%

ROCE

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+100.3%

Fast-growing sales (100.3% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

-36%

Weak — only -36% of profit becomes cash

FCF Margin

-465.2%

Burning cash (-465.2%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

—

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

0.0x

Attractive valuation — P/E 0.0

P/E under 10. The price tag is small relative to last year's profit.

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial